Abstract: New human therapeutic monoclonal antibodies, which are directed against neutrophil proteinase 3. The monoclonal antibodies are specifically directed against a conformational epitope of the neutrophil proteinase 3 and are capable of inhibiting by at least 30% the production for reactive oxygen derivatives by neutrophils. Also, a pharmaceutical composition including as an active substance at least the monoclonal antibody, and a method for early treatment and/or prevention of relapse of granulomatosis with polyangiitis, which includes the administration of the pharmaceutical composition.

Abstract: The present invention relates to peptidyl phosphonate esters compounds and their use selective inhibitors of proteinase 3, in particular for treating or diagnosing inflammator autoimmune and cancer disorders. More specifically, the invention concerns nov peptidyl phosphonate esters compounds, including without limitation, compounds with Asp-Tyr-Asp-Ala or Pro-Tyr-Asp-Ala, Pro-Tyr-Asp-Avl, Val-Tyr-Asp-Avl peptide structure or their derivatives.